<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jana S</submitter><funding>Swedish Cancer Research Foundation</funding><funding>Ministry of Human Resource Development</funding><funding>LUA/ALF and the VAJRA Faculty Scheme</funding><funding>Barncancerfonden</funding><funding>Department of Science and Technology, Ministry of Science and Technology, India</funding><funding>Swedish Research Council</funding><funding>IngaBritt och Arne Lundbergs Forskningsstiftelse</funding><funding>Department of Biotechnology, Ministry of Science and Technology, India</funding><pagination>RP88256</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11415074</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12</volume><pubmed_abstract>In tumors with WT p53, alternate mechanisms of p53 inactivation are reported. Here, we have identified a long noncoding RNA, &lt;i>PITAR&lt;/i> (&lt;i>p&lt;/i>53 &lt;i>I&lt;/i>nactivating &lt;i>T&lt;/i>RIM28 &lt;i>A&lt;/i>ssociated &lt;i>R&lt;/i>NA), as an inhibitor of p53. &lt;i>PITAR&lt;/i> is an oncogenic Cancer/testis lncRNA and is highly expressed in glioblastoma (GBM) and glioma stem-like cells (GSC). We establish that &lt;i>TRIM28&lt;/i> mRNA, which encodes a p53-specific E3 ubiquitin ligase, is a direct target of &lt;i>PITAR. PITAR&lt;/i> interaction with &lt;i>TRIM28&lt;/i> RNA stabilized &lt;i>TRIM28&lt;/i> mRNA, which resulted in increased TRIM28 protein levels and reduced p53 steady-state levels due to enhanced p53 ubiquitination. DNA damage activated &lt;i>PITAR&lt;/i>, in addition to p53, in a p53-independent manner, thus creating an incoherent f</pubmed_abstract><journal>eLife</journal><pubmed_title>&lt;i>PITAR&lt;/i>, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing &lt;i>TRIM28&lt;/i> mRNA.</pubmed_title><pmcid>PMC11415074</pmcid><funding_grant_id>NPDF</funding_grant_id><funding_grant_id>LU2020-0017</funding_grant_id><funding_grant_id>(VJR/2021/000008</funding_grant_id><funding_grant_id>2022–01262</funding_grant_id><funding_grant_id>STARS</funding_grant_id><funding_grant_id>211416Pj01H</funding_grant_id><funding_grant_id>2022-01262</funding_grant_id><funding_grant_id>PR2021-0026</funding_grant_id><pubmed_authors>Gupta B</pubmed_authors><pubmed_authors>Mahale S</pubmed_authors><pubmed_authors>Mondal M</pubmed_authors><pubmed_authors>Jha N</pubmed_authors><pubmed_authors>Somasundaram K</pubmed_authors><pubmed_authors>Prasasvi KR</pubmed_authors><pubmed_authors>Santosh V</pubmed_authors><pubmed_authors>Kanduri C</pubmed_authors><pubmed_authors>Chowdhury A</pubmed_authors><pubmed_authors>Jana S</pubmed_authors><pubmed_authors>Kandasami L</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>PITAR&lt;/i>, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing &lt;i>TRIM28&lt;/i> mRNA.</name><description>In tumors with WT p53, alternate mechanisms of p53 inactivation are reported. Here, we have identified a long noncoding RNA, &lt;i>PITAR&lt;/i> (&lt;i>p&lt;/i>53 &lt;i>I&lt;/i>nactivating &lt;i>T&lt;/i>RIM28 &lt;i>A&lt;/i>ssociated &lt;i>R&lt;/i>NA), as an inhibitor of p53. &lt;i>PITAR&lt;/i> is an oncogenic Cancer/testis lncRNA and is highly expressed in glioblastoma (GBM) and glioma stem-like cells (GSC). We establish that &lt;i>TRIM28&lt;/i> mRNA, which encodes a p53-specific E3 ubiquitin ligase, is a direct target of &lt;i>PITAR. PITAR&lt;/i> interaction with &lt;i>TRIM28&lt;/i> RNA stabilized &lt;i>TRIM28&lt;/i> mRNA, which resulted in increased TRIM28 protein levels and reduced p53 steady-state levels due to enhanced p53 ubiquitination. DNA damage activated &lt;i>PITAR&lt;/i>, in addition to p53, in a p53-independent manner, thus creating an incoherent f</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-01T10:04:12.131Z</modification><creation>2025-04-04T08:21:56.763Z</creation></dates><accession>S-EPMC11415074</accession><cross_references><pubmed>39302097</pubmed><doi>10.7554/eLife.88256</doi></cross_references></HashMap>